A single-arm prospective single-centre trial of stilbestrol in combination with immune-targeted chemotherapy in patients with peritoneal metastatic carcinoma refractory to conventional treatment

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400083649

Enrollment

Unknown

Registered

2024-04-29

Start date

2024-04-30

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal metastatic carcinoma

Interventions

intervention group:stilbestrol in combination with immune-targeted chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age over 18 years old; 2. Patients with peritoneal metastatic cancer confirmed by laparoscopy, caesarean section or imaging who have failed conventional treatment or are intolerant to conventional treatment or lack of effective treatment. 3. Primary lesions are mainly gastric cancer, colorectal cancer, ovarian cancer and pancreatic cancer confirmed by histology. 4. Physical status score (ECOG) 0-2; 5. expected survival = 3 months; 6. voluntary participation in the clinical study and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. uncontrolled active infection. 2. acute or chronic (graft-versus-host disease) GVHD. 3. Concomitant other uncontrolled malignancies. 4. active hepatitis B or C with HIV infection = upper limit of normal; and 5. Suffering from coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral haemorrhage and other serious diseases. 6. Unstable pulmonary embolism, deep vein embolism or other major arterial/venous thromboembolic events within 6 months prior to enrolment; 7. history of uncontrollable psychiatric illness. 8. existing medical or mental status history or laboratory abnormalities that may increase the risk associated with participation in the study or administration of the study drug. 9. patients with medical conditions for which written informed consent has been signed or study procedures adhered to who are unwilling or unable to comply with the requirements of the study;

Design outcomes

Primary

Measure	Time frame
ORR rate for 6 cycles;	—

Secondary

Measure	Time frame
PFS;OS;ORR;DCR;safety;	—

Countries

china

Contacts

Public Contactzhang chang hua

The Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen)

zhangchanghua@sysush.com+86 136 7898 7415

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026